NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Ataraxis AI

Ataraxis AI

Private
New York City, New YorkHealthcare & Life Scienceshttps://www.ataraxis.ai/

Last Round

Early Funding

Apr 21, 2025

Est. Valuation

$68.4M

Total Funding Raised

$48.8M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Ataraxis AI is a precision oncology company that develops AI-powered diagnostic tools to personalize cancer treatment selection and prognosis.

Sector

Healthcare & Life Sciences

Verticals

Medical AI, Medical Imaging, Healthcare Analytics

Business Model

B2B

Customer Profile

Usage-Based SaaS

AI Layer

Application

Keywords

medical AIbreast cancer diagnosticsprecision medicineAI diagnosticsoncology AIdigital pathologyclinical decision supportmedical imagingpredictive diagnosticshealthcare analyticsfoundation modelvision transformerAI-native diagnosticscomputational pathologyfrontier AI lab

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ataraxis AI Comps

Public and private peers based on sector, stage, and business model.

Ataraxis AI comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Ataraxis AI Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingApr 21, 2025
Series AMar 5, 2025
SeedOct 31, 2024

Key People

Founding team and executive leadership

Krzysztof Geras

Chief Scientific Officer, Co-Founder

Founding Team

Jan Witowski

CEO Founder

Founding Team

Ataraxis AI Investors

Notable investors and investment history

Ataraxis AI investors
InvestorRounds
Bertelsmann InvestmentsSeries A
Floating PointSeries A
Founders FundSeries A
Floating Point AdvisorsSeries A
Thiel BioSeries A
Obvious VenturesSeries A, Seed
Floating Point CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 30, 2026

    Ataraxis Breast CTX estimates individualized chemotherapy benefits for patients.

  • Mar 12, 2026

    AI pioneer Yann LeCun joins as an advisor.

Ataraxis AI Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ataraxis AI Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ataraxis AI's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range40
Year Founded2023
Last FundingApr 21, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.